Elacestrant (Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial

June 17, 2022 | Aditya Bardia, MD, MPH

Share on:

Dr Aditya Bardia reviews recently published data from the EMERALD trial on elacestrant versus endocrine therapy in patients with ER-positive/HER2-negative (ER+/HER2–) breast cancer.
Funding supported by Stemline Therapeutics. Content independently developed by OncLive.

onclive rapid readouts logo